BRAINSTORM CELL THERAPEUTICS INC.
BRAINSTORM CELL THERAPEUTICS INC. (BCLI): 2 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.5 months
D/E -1.07 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for BRAINSTORM CELL THERAPEUTICS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.9M
Cash
$206K
Quarterly Burn
$1.3M
Runway
0.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in BRAINSTORM CELL THERAPEUTICS INC.'s pipeline?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BRAINSTORM CELL THERAPEUTICS INC.'s lead drug candidate?
BRAINSTORM CELL THERAPEUTICS INC.'s most advanced tracked candidate is nurown (Preclinical) for Alzheimer's disease (AD).
What is BRAINSTORM CELL THERAPEUTICS INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BRAINSTORM CELL THERAPEUTICS INC. has approximately 0.5 months of cash runway.
What is BRAINSTORM CELL THERAPEUTICS INC.'s market capitalization?
BRAINSTORM CELL THERAPEUTICS INC.'s market capitalization is approximately $8.9M.
Who is the CEO of BRAINSTORM CELL THERAPEUTICS INC.?
Mr. Chaim Lebovits is the chief executive officer of BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
Get the full picture on BRAINSTORM CELL THERAPEUTICS INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.